about
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideThe tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbillivirusesOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesMeasles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice.Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entry.Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancerOncolysis by paramyxoviruses: preclinical and clinical studies.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.Measles virus for cancer therapy.The Na+/I- symporter (NIS): mechanism and medical impact.In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer modelsUse of attenuated paramyxoviruses for cancer therapy.Retargeting of viruses to generate oncolytic agents.Progress of oncolytic viruses in sarcomas.Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.Oncolytic virotherapy for multiple myeloma: past, present, and future.Oncolytic Virotherapy: A Contest between Apples and Oranges.Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.How to train your oncolytic virus: the immunological sequel.High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.Viral mediated cell fusion: viral fusion--the making, or breaking, of a tumour?
P2860
Q24647228-55D0149B-5D69-413A-84E3-B43E3C8B8AFFQ33820699-65B79D04-EED8-497C-ACB1-718E828B3B19Q33924550-966797BC-9558-4B48-92B8-6E1F10D75FC0Q34132250-C63D90F9-D9CC-48B7-90D6-D65C75C358EBQ34178182-D9AE2208-8166-4A66-AA4F-B48427D37F0AQ34292273-CA48FAA4-B646-4F8C-9CB4-2FE74584E0AEQ34997475-0367B569-F4B9-4515-BF7D-E85A40B33D8EQ35861933-F7F9BCE8-6755-4AD1-98C0-39D1D8573919Q35861936-37B14EF8-A921-4B04-B347-59153B3942AFQ37115384-5700E762-775F-4397-8389-96302F48C1C5Q37336713-88F28F0F-3819-4C76-B824-007B1FECD26AQ37388577-190DC2BD-66F7-4A6C-8E71-90E967E18914Q37494004-332238CA-0F72-43A6-8A3C-5D999E43FA56Q37629550-33999FD4-8CFA-45E8-872A-A77B88DC981FQ37810599-BEFE7342-74AE-48D9-BEE4-628560062BFDQ37982062-7661F852-03A5-40B2-8FF3-826983787BE3Q37982449-A43E6FF5-AF3F-4E20-AE44-2A99CBD7D46CQ38692304-E789827C-C176-441E-A9AA-CE468EA92013Q38803056-7916D058-DDD9-465B-95BB-8C029D1F7979Q39230055-3E1B85B1-AAE8-4FDD-93F6-666DCCB60BE0Q40075614-F0814014-9ABD-4455-9151-DA49B42CB4FAQ40176322-4940C8B4-8B4A-401C-A13F-2BF83EB88DD1Q40581942-2C863D07-B680-4FD8-8FD7-A8B793BF61B4Q40611325-7B0BBCC2-5549-496C-B13E-CCD1F44D7CC8Q41498081-428B67F7-4463-44A8-892D-694150431923Q45863222-8E62F060-9A37-4721-9ED1-FB179508B728Q45865364-1B3660C8-FD92-49DD-A571-138A39FFD017
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Oncolytic measles viruses for cancer therapy.
@ast
Oncolytic measles viruses for cancer therapy.
@en
type
label
Oncolytic measles viruses for cancer therapy.
@ast
Oncolytic measles viruses for cancer therapy.
@en
prefLabel
Oncolytic measles viruses for cancer therapy.
@ast
Oncolytic measles viruses for cancer therapy.
@en
P2860
P1476
Oncolytic measles viruses for cancer therapy.
@en
P2093
Takafumi Nakamura
P2860
P304
P356
10.1517/14712598.4.10.1685
P407
P577
2004-10-01T00:00:00Z